✦ LIBER ✦

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study

✍ Scribed by Alain Ravaud; Thomas Cerny; Catherine Terret; Jantien Wanders; Binh Nguyen Bui; Dagmar Hess; Jean-Pierre Droz; Pierre Fumoleau; Chris Twelves

Book ID: 116428461
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 108 KB
Volume: 41
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2004.12.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical and pharmacokinetic stu

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

✍ C Terret; S Zanetta; H Roché; J.H.M Schellens; M.N Faber; J Wanders; M Ravic; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 218 KB

Phase I and pharmacokinetic study of Yon

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

✍ C. Twelves; K. Hoekman; A. Bowman; J.B. Vermorken; A. Anthoney; J. Smyth; C. van 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 279 KB

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3&#xa0;weeks in solid tumours: An ECSG/EORTC study

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study